When breastfeeding is unavailable, optimization of infant nutrition is a principal factor required to further support immune development in early life. Research indicates that commercially produced HMOs can mimic some of the health-promoting effects of the HMOs present in human milk.
HMOs rich in galactosyllactose, such as GOS 70, allow for the creation of formulas that are closer to the profile of natural human milk to provide bottle-fed babies with the benefits of these essential components of breast milk.